MedTrace Logo

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

NCT03430661 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2025-07-03

No results posted yet for this study

Summary

The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female subjects

Conditions

  • Healthy

Interventions

DRUG

ACT-246475

Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection

DRUG

Clopidogrel

Tablet for oral administration (300 or 600 mg)

DRUG

Prasugrel

Tablet for oral administration (60 mg)

DRUG

Placebo

Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution

DRUG

Ticagrelor

Tablet for oral administration (180 mg)

Sponsors & Collaborators

  • Viatris Innovation GmbH

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Viatris Innovation GmbH

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-24
Primary Completion
2019-05-20
Completion
2019-05-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03430661 on ClinicalTrials.gov